Merck Serono Expands Biopharmaceutical R&D Facility

Merck is investing € 65 million in a laboratory building for R&D Discovery Technologies at Merck Serono

15-Sep-2015 - Germany

Merck Serono announced the expansion of its R&D facility in Darmstadt, Germany. Merck is investing € 65 million in a new laboratory building that will span more than 16,000 square meters and accommodate approximately 200 current employees whose focus will be accelerating innovation in R&D.

Merck KGaA

Laboratories and offices span 16,000 square meters for 200 employees

The new building will unite different functions within R&D Discovery Technologies at Merck Serono, including Molecular Pharmacology, Medicinal Chemistry, Computational Chemistry, Molecular Interactions and Biophysics, Protein Engineering and Antibody Technologies, and Protein and Cell Sciences.

The research building, when complete in fall of 2017, will be located within the new "Pharma Square" on the Merck campus in Darmstadt. Merck is thus uniting a significant part of its R&D activities in a single area, creating ideal conditions for the advancement of its biopharmaceutical pipeline.

With approximately 2,000 scientific and clinical development professionals working across four R&D hubs - Darmstadt, Germany, the largest R&D site; Boston, US; Tokyo, Japan; and Beijing, China - Merck Serono endeavors to make a meaningful difference in the lives of people with serious medical needs. The core areas of R&D focus for Merck Serono are oncology, immuno-oncology, and immunology.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances